Praxis Precision Medicines: Between FDA Approval and Billion-Dollar Market

Praxis Precision Medicines is a US biopharmaceutical company that researches therapies for severe CNS disorders and plans to generate revenue through direct sales of its own active substances as well as licensing partnerships with pharmaceutical companies. The potential for stock growth is primarily driven by two advanced candidates, the active substance Ulixacaltamid for essential tremor and Relutrigin for rare genetic epilepsies, which could open up large markets upon FDA approval starting in 2026/2027. With cash reserves of approximately...